STAT3 and prostate carcinoma: SCO also exerted antitumor effects on prostate cancer cells by inhibiting the transcription of STAT3 target genes, such as cyclin D1, c-Myc, survivin, Bcl-2 and Socs3, and decreasing the phosphorylation and nuclear accumulation of STAT3, but not JAK2 (81).